Cleveland BioLabs, Inc. (NASDAQ:CBLI)

CAPS Rating: 1 out of 5

The Company is engaged in the discovery, development and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins.

Results 1 - 20 of 25 : 1 2 Next »

Recs

1
Member Avatar zzlangerhans (99.79) Submitted: 5/27/2015 3:03:44 PM : Underperform Start Price: $3.23 CBLI Score: +0.92

The game of low float microcap bioturd whack-a-mole continues apace, with yesterday's late afternoon entry of Cleveland Biolabs. This outfit has truly been one of the most pathetic in the sector since its Garza-fueled glory days came to an end in 2011. Their quarterly conference calls are filled with mealy-mouthed double talk about their supposed negotiations with BARDA regarding contracts that never seem to be awarded. This year, having claimed at one point that the contracts were already signed, management is now claiming they are still in discussions with the DoD and warning that the deadline for next year's funding is September 30. Any guesses as to whether any funds will appear? The only fun part of reading the CC transcript was the Q&A at the end where their former lapdog analysts chewed into management for their freespending ways.

The purported excuse for the stock double yesterday was that the company will be presenting at ASCO this week. Yes, they'll have a poster of phase I data of Entolimod in healthy subjects. I'm sure attendees will be racing out of the checkpoint inhibitor and HER2 inhibitor sessions to crowd around the Cleveland BioLabs poster like it's the Mona Lisa. In reality, the company is desperately short of cash to the extent that they were forced to sell off half their pipeline in April for 4M and a 2% royalty. That's really what days like yesterday are all about - share price manipulation by bottom tier brokerages that will facilitate dilutive financing. It's a game of survival where the loser is always the last group of fools to buy.

I had a little too much on my plate to get to Cleveland BioLabs last night and the pump didn't last long enough this morning for me to get my short in. It's too bad, I could have used another couple thousand bucks to accelerate my early retirement by another shift. Hopefully the pump will get a second wind this week and I'll get my chance to put another stinker in the win column.

Recs

0
Member Avatar pchop12316 (78.44) Submitted: 5/27/2015 10:23:44 AM : Underperform Start Price: $3.41 CBLI Score: +5.74

no confidence

Recs

0
Member Avatar warrenout (99.63) Submitted: 5/27/2015 9:08:10 AM : Underperform Start Price: $3.91 CBLI Score: +18.08

following zzlangerhans

Recs

0
Member Avatar stemcells2011 (93.25) Submitted: 3/19/2015 5:37:41 PM : Outperform Start Price: $3.87 CBLI Score: -18.88

Not sure why I green thumbed this as it's probably going to zero.

Recs

0
Member Avatar AndrewGreenBull (98.94) Submitted: 4/8/2014 10:53:31 AM : Outperform Start Price: $0.69 CBLI Score: +352.83

Should be back to $1 soon

Recs

0
Member Avatar turningpoint84 (84.40) Submitted: 7/22/2013 12:00:53 PM : Outperform Start Price: $1.67 CBLI Score: +68.31

I have a good feeling about them.

Recs

0
Member Avatar JULGABANN (57.42) Submitted: 4/9/2013 5:45:23 PM : Outperform Start Price: $1.60 CBLI Score: +61.85

Cleveland is way undervalued at this point, 2 drug applications for CBLB502 and a BARDA deal on the way... this will double in weeks and be a great buy and hold stock for years to come.

Recs

0
Member Avatar thecashmen (22.02) Submitted: 6/4/2012 4:03:33 PM : Underperform Start Price: $2.07 CBLI Score: +10.33

big pop big drop

Recs

0
Member Avatar SamsaricSufferer (52.95) Submitted: 4/8/2012 3:57:20 PM : Outperform Start Price: $1.56 CBLI Score: +52.86

Bounce coming. Recent news was not the death knell that was touted.

Recs

0
Member Avatar TMFBiologyFool (95.75) Submitted: 4/5/2012 1:24:45 PM : Outperform Start Price: $1.68 CBLI Score: +40.41

Overreaction to BARDA decision looks like a buying opportunity.

Recs

0
Member Avatar oznola (< 20) Submitted: 2/27/2012 10:00:26 PM : Outperform Start Price: $3.89 CBLI Score: -72.00

Price action indicates upward trend in monthly, weekly and daily time frame. Volume spike + Chaikin Oscillator indicates bullish trend.

Recs

0
Member Avatar dcsilver (61.70) Submitted: 12/29/2011 11:46:14 AM : Outperform Start Price: $2.76 CBLI Score: -52.01

Stock fell off in July. Since then, heavy insider purchases and a thumbs up from zzlangerhan.

Recs

0
Member Avatar Dynablob (< 20) Submitted: 3/5/2011 12:16:45 PM : Outperform Start Price: $7.05 CBLI Score: -114.28

Asymmetric risk/reward. BARDA grant would further legitimize science behind 502, leading to domestic & international government orders. Total market size should be $300-$500 million for the drug, and CBLI should get good margins on a large order.

Recs

0
Member Avatar 650driver (38.88) Submitted: 12/3/2010 1:22:32 PM : Outperform Start Price: $7.09 CBLI Score: -127.89

A golfing buddy of mine told me his son had recently bought 50,000 shares of a bioteck co and asked me to look at it for him. I rarely buy stocks under $ 10 and almost never one that dosn't pay at least a 4 % div.
I suggested to my buddie that his son should have a winner and if he could afford a little risk he should jump on it also. I then bouhgt 5000 shrs and several options.
Todays news granting "orphan status" from tha FDA intiated this post. If this drug comes anywhere near doing what their studies show, it couyld be a triple bagger very quickly. I bought between 6.00 and 6.30 it croosed 9.95 this am.

Recs

0
Member Avatar longterm90 (< 20) Submitted: 10/6/2010 8:58:57 AM : Outperform Start Price: $5.43 CBLI Score: -123.85

Won a DoD contract for $45 million. Lots of news out on this one in the past few weeks including a patent being granted.

Recs

1
Member Avatar Interpol10 (61.99) Submitted: 7/19/2010 9:23:14 PM : Outperform Start Price: $3.50 CBLI Score: -108.62

If all goes well with CBLI's research, we can hope to see a drug that increases human resistance to radiation. In my opinion, a truly groundbreaking discovery with an obtainable goal in sight, and their first round of testing going well only adds to my optimism.

Recs

0
Member Avatar diversified1 (83.55) Submitted: 10/29/2007 11:48:42 PM : Outperform Start Price: $12.60 CBLI Score: -119.59

Read the Bios of their researchers, you will be impressed. In this world the projects they are working on are timely and amazing.

Recs

0
Member Avatar sixfigsdn (< 20) Submitted: 9/18/2007 7:21:54 PM : Outperform Start Price: $12.00 CBLI Score: -119.03

Expecting 200M+ dod contract to develope ARS drug in October.

Recs

0
Member Avatar BigWhereItCounts (< 20) Submitted: 7/14/2007 8:22:56 PM : Underperform Start Price: $11.00 CBLI Score: +115.10

Way too high of price/sales and price/book

Recs

0
Member Avatar zaphelps (86.89) Submitted: 5/29/2007 11:11:28 AM : Outperform Start Price: $9.28 CBLI Score: -112.88

The company focuses on radiation drug discovery. The drugs they are working on target only cancer cells and don't harm normal tissues. Their inital target is to protect humans from radiation as a result of a terrorist attack or nuclear accident.

Results 1 - 20 of 25 : 1 2 Next »

Featured Broker Partners


Advertisement